122 related articles for article (PubMed ID: 38349618)
1. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S
Expert Opin Biol Ther; 2024 Feb; ():1-9. PubMed ID: 38349618
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
[TBL] [Abstract][Full Text] [Related]
3. A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects.
Lee HA; Kim S; Seo H; Kim S
Expert Opin Investig Drugs; 2023; 32(10):959-966. PubMed ID: 37870163
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.
Yu KS; Jang IJ; Lim HS; Hong JH; Kim MG; Park MK; Cho DY; Park MS; Chung JY; Ghim JL; Lee S; Yoon SK; Kwon IS; Lee SJ; Kim SH; Bae YJ; Cha JB; Furst DE; Keystone E; Kay J
Clin Transl Sci; 2021 Jul; 14(4):1280-1291. PubMed ID: 33503313
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
Yu KS; Ryu H; Shin D; Park M; Hwang J; Moon SJ; Kim MG; Keystone E; Smolen JS; Kim S; Bae Y; Jeon D; Jang J; Yang G; Bae J; Lee J; Burmester GR
Expert Opin Biol Ther; 2024 Jun; ():1-9. PubMed ID: 38905143
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects.
Ding Y; Liu Y; Dou C; Guo S
J Bone Oncol; 2023 Oct; 42():100499. PubMed ID: 37701913
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial.
Guo Y; Guo T; Di Y; Xu W; Hu Z; Xiao Y; Yu H; Hou J
Expert Opin Biol Ther; 2023; 23(8):705-715. PubMed ID: 36892190
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males.
Vogg B; Poetzl J; El Galta R; Fuhr R; Schwebig A; Sekhar S
Expert Opin Biol Ther; 2024; 24(1-2):91-100. PubMed ID: 38269652
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
[TBL] [Abstract][Full Text] [Related]
10. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.
Nakov R; Gattu S; Wang J; Velinova M; Schaffar G; Skerjanec A
Br J Clin Pharmacol; 2018 Dec; 84(12):2790-2801. PubMed ID: 30079636
[TBL] [Abstract][Full Text] [Related]
11. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: A randomised, double-blind, parallel-group, Phase 1 trial.
Maurer M; Saini SS; McLendon K; Wabnitz P; Kim S; Ahn K; Kim S; Lee S; Grattan C
Clin Transl Allergy; 2022 Nov; 12(11):e12204. PubMed ID: 36434739
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects.
Wang S; Yang X; Huang J; Yang S; Wu Q; Chen H; Wu S; Dou C; Yang G; Xiang Y
Expert Opin Investig Drugs; 2022 Oct; 31(10):1133-1142. PubMed ID: 36045484
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects.
Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W
Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787
[TBL] [Abstract][Full Text] [Related]
17. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
[TBL] [Abstract][Full Text] [Related]
18. The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva®) in healthy Chinese subjects: A single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.
Hou J; Hu Z; Xu W; Di Y; Song C; Wu F; Liu J; Guo Y
Int Immunopharmacol; 2022 Jun; 107():108666. PubMed ID: 35286913
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X
Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
